Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Four-Dimensional Flow MRI of Abdominal Veins: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. New Trends in Vascular Imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Short-term morbidity and mortality following radical cystectomy: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin D levels and the risk of prostate cancer and prostate cancer mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Radical prostatectomy (RP) is a curatively intended treatment option for clinically localized non-metastatic prostate cancer (PCa). Novel biomarkers could refine treatment choice based on a better identification of men at risk of biochemical recurrence (BCR) following therapy. The urokinase plasminogen activator receptor (uPAR) system is a promising biomarker of aggressiveness in many cancers. The predictive value of uPAR after curatively intended treatment for PCa remains to be elucidated. This was a prospective evaluation of uPAR analysis in men with prostate cancer (Copenhagen uPAR prostate cancer (CuPCA) database). Risk of BCR following RP was analyzed using cumulative incidences with competing risk and tested with Gray's test. Associations between quartile groups of uPAR levels and BCR were assessed with uni- and multivariate Cox proportional hazards. In total, 532 men were included. With more advanced tumor stage, Gleason score (GS), and prostate-specific antigen (PSA) the uPAR I-III + II-III plasma levels increased. Quartile levels of plasma uPAR I-III, I-III + II-III showed no significant association between the risk of BCR and the plasma uPAR levels in uni- and multivariate analysis. Despite increased levels of uPAR I-III + II-III in advanced tumor stage, intact and cleaved uPAR levels were not associated with BCR and are not predictive biomarkers for BCR following curatively intended treatment of PCa. It is unlikely that further studies of uPAR in RP treated patients is needed.

OriginalsprogEngelsk
Artikelnummer877
TidsskriftDiagnostics
Vol/bind10
Udgave nummer11
Sider (fra-til)877
Antal sider9
ISSN2075-4418
DOI
StatusUdgivet - nov. 2020

ID: 62034040